ストックスクリーナーアプリを入手
12.79
2.65%
0.33
アフターアワーズ：
12.79
前日終値:
$12.46
開ける：
$12.37
24時間の取引高:
2.19M
Relative Volume:
2.00
時価総額：
$1.29B
収益：
-
当期純損益:
$-167.48M
株価収益率:
-5.5609
EPS:
-2.3
ネットキャッシュフロー:
$-197.47M
1週間 パフォーマンス:
+0.31%
1か月 パフォーマンス:
-6.09%
6か月 パフォーマンス:
-2.52%
1年 パフォーマンス:
-7.65%
1日の値動き範囲:
$12.11
$13.00
1週間の範囲:
$12.11
$13.00
52週間の値動き範囲:
$11.94
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
名前
Day One Biopharmaceuticals Inc
セクター
電話
650 484-0899
住所
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
12.79 | 1.29B | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-09 | 繰り返されました | Needham | Buy |
| 2024-08-01 | アップグレード | BofA Securities | Underperform → Buy |
| 2024-04-24 | 繰り返されました | Needham | Buy |
| 2023-04-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-02-08 | 開始されました | CapitalOne | Overweight |
| 2023-02-03 | 開始されました | Oppenheimer | Perform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-12-05 | 開始されました | Goldman | Buy |
| 2022-12-01 | 開始されました | BofA Securities | Buy |
すべてを表示
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,537 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Day One Biopharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference - StockTitan
Franklin Resources Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk - Nasdaq
The Children's Brain Tumor Network Partners with Day One Biopharmaceuticals to Drive New Therapies for Pediatric Brain Tumors - Marketscreener.com
Wellington Management Group LLP Acquires 423,543 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day one Biopharmaceuticals head of R&D sells $399,339 in stock - Investing.com
Charles Schwab Investment Management Inc. Acquires 64,700 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
689,655 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Frazier Life Sciences Management L.P. - MarketBeat
Janus Henderson Group PLC Has $30.31 Million Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Samsara BioCapital LLC Has $2.05 Million Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Fmr LLC Boosts Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Erste Asset Management GmbH Invests $725,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Braidwell LP Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Algert Global LLC Has $996,000 Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Vestal Point Capital LP Boosts Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) PT at $35.71 - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Buy” by Analysts - Defense World
Dream Finders Homes Inc. (DFH) Crossed Above the 50-Day Moving Average: What That Means for Investors - MSN
Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts? - Insider Monkey
10 Best Up and Coming Stocks To Buy According to Analysts - Insider Monkey
Glioma Market Size in the 7MM is approximately USD 1,000 million in 2023, estimated DelveInsight - The Globe and Mail
What Analysts Were Expecting After Day One Biopharmaceuticals Inc (NASDAQ: DAWN) fell -2.06% - Stocks Register
When the Price of (DAWN) Talks, People Listen - Stock Traders Daily
Day One Biopharmaceuticals announces R&D leadership change By Investing.com - Investing.com Australia
Day One Biopharmaceuticals announces R&D leadership change - Investing.com India
Day One Biopharmaceuticals announces executive retirement By Investing.com - Investing.com UK
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development - GlobeNewswire
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? - MSN
Day one Biopharmaceuticals COO sells shares worth $34,372 By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals CEO sells $139,420 in stock - Investing.com
Day one Biopharmaceuticals COO sells shares worth $34,372 - Investing.com
Day One Biopharmaceuticals CEO sells $139,420 in stock By Investing.com - Investing.com UK
First Turn Management LLC Invests $13.20 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Large Increase in Short Interest - MarketBeat
First Week of July 2025 Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Day One Biopharmaceuticals to Present at Piper Sandler Healthcare Conference | DAWN Stock News - StockTitan
59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLP - MarketBeat
(DAWN) Trading Advice - Stock Traders Daily
TimesSquare Capital Management LLC Has $25.46 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in Stock - MarketBeat
FMR LLC Bolsters Position in Day One Biopharmaceuticals Inc - GuruFocus.com
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded at TD Cowen - MarketBeat
Day one biopharmaceuticals head of R&D sells $8,010 in stock By Investing.com - Investing.com Canada
Day one biopharmaceuticals head of R&D sells $8,010 in stock - Investing.com
Day One Biopharmaceuticals Inc (DAWN) 財務データ
収益
当期純利益
現金流量
EPS
Day One Biopharmaceuticals Inc (DAWN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
Nov 18 '24 |
Sale |
13.21 |
10,554 |
139,420 |
108,377 |
| Blackman Samuel C. | HEAD OF R&D |
Nov 18 '24 |
Sale |
13.21 |
2,206 |
29,142 |
1,064,015 |
| Dubow Adam | GENERAL COUNSEL |
Nov 18 '24 |
Sale |
13.21 |
3,165 |
41,810 |
32,162 |
| York Charles N II | COO, CFO AND SECRETARY |
Nov 18 '24 |
Sale |
13.21 |
2,602 |
34,373 |
240,133 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):